US20130150324A1 - Efficient lipid delivery to human tear film using a salt-sensitive emulsion system - Google Patents

Efficient lipid delivery to human tear film using a salt-sensitive emulsion system Download PDF

Info

Publication number
US20130150324A1
US20130150324A1 US13/708,783 US201213708783A US2013150324A1 US 20130150324 A1 US20130150324 A1 US 20130150324A1 US 201213708783 A US201213708783 A US 201213708783A US 2013150324 A1 US2013150324 A1 US 2013150324A1
Authority
US
United States
Prior art keywords
composition
emulsion
dry eye
nge
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/708,783
Other languages
English (en)
Inventor
Peter A. Simmons
Joseph G. Vehige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130150324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US13/708,783 priority Critical patent/US20130150324A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIMMONS, PETER A., VEHIGE, JOSEPH G.
Publication of US20130150324A1 publication Critical patent/US20130150324A1/en
Priority to US15/078,377 priority patent/US9907826B2/en
Priority to US15/878,259 priority patent/US10888598B2/en
Priority to US17/128,794 priority patent/US20210245512A1/en
Priority to US18/410,273 priority patent/US20240293491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention is directed to artificial tears suitable for treating dry eye syndrome and other ocular conditions in a human or other mammal.
  • Typical symptoms of keratoconjunctivitis or dry eye include feelings of dryness, burning, and a sandy-gritty eye sensation that can worsen during the day. Symptoms may also be described as itchy, scratchy, stingy or tired eyes. Other symptoms include pain, redness, a pulling sensation, and pressure behind the eye. The damage to the eye surface resulting from dry eye increases discomfort and sensitivity to bright light and both eyes usually are affected.
  • blinking coats the eye with tears, symptoms are worsened by activities in which the rate of blinking is reduced due to prolonged use of the eyes. These activities include prolonged reading, computer usage, driving or watching television. Symptoms increase in windy, dusty or smoky areas, in dry environments, high altitudes including airplanes, on days with low humidity, and in areas where an air conditioner, fan, or heater, is being used. Symptoms are less severe during cool, rainy, or foggy weather, and in humid places. Most people who have dry eyes experience mild irritation with no long-term effects. However, if the condition is left untreated or becomes severe, it can produce complications that can cause eye damage, resulting in impaired vision or possibly in the loss of vision.
  • Having dry eyes for a prolonged period of time can lead to tiny abrasions on the surface of the eyes.
  • the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells sometimes due to activation of T cells acting against those cells.
  • Some severe cases result in thickening of the corneal surface, corneal erosion, punctate keratopathy, epithelial defects, corneal ulceration, corneal neovascularization, corneal scarring, corneal thinning, and even corneal perforation.
  • An abnormality of any one of the three layers of tears which produces an unstable tear film may result in symptoms of keratitis sicca.
  • Keratoconjunctivitis sicca is usually due to inadequate tear production.
  • the aqueous tear layer is affected, resulting in aqueous tear deficiency or lacrimal hyposecretion.
  • the lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women.
  • causes include idiopathic, congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation.
  • Sjögren's syndrome and autoimmune diseases associated with Sjögren's syndrome are also conditions associated with aqueous tear deficiency.
  • Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition.
  • Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition.
  • Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this condition, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too “salty” or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
  • Aging is one of the most common causes of dry eyes. This is due to the fact that tear production decreases with age. It may be caused by thermal or chemical burns, or by adenoviruses. Diabetics are also at increased risk for dry eye.
  • An eye injury or other problem with the eyes or eyelids can cause keratoconjunctivitis sicca. Disorders of the eyelid can impair the complex blinking motion required to spread tears.
  • Abnormalities of the lipid tear layer caused by blepharitis and rosacea and abnormalities of the mucin tear layer caused by vitamin A deficiency, trachoma, diphtheric keratoconjunctivitis mucocutaneous disorders and certain topical medications may cause dry eye or keratoconjunctivitis sicca.
  • Dry eyes can usually be diagnosed by the symptoms alone. Tests can determine both the quantity and the quality of the tears. A slit lamp examination can be performed to diagnose dry eyes and to document any damage to the eye. A Schirmer's test can measure the amount of moisture bathing the eye. This test is useful for determining the severity of the condition.
  • Lubricating tear ointments can be used during the day, but they generally are used at bedtime due to poor vision after application. They contain white petrolatum, mineral oil, and similar lubricants. They serve as a lubricant and an emollient. Depending on the severity of the condition, ointments may be applied from every hour to just at bedtime. Ointments should not be used with contact lenses. Inflammation occurring in response to tears film hypertonicity can be suppressed by mild topical steroids or with topical immunosuppressants such as cyclosporine.
  • the present invention is comprised of an artificial tear emulsion of the following formulation:
  • the Table I formulation includes the concentrations of actives and/or excipients as disclosed above which can be in concentrations which vary from what is stated above. The variation may be such that the amounts are “about” what is stated above so long as that amount would be found bioequivalent by a regulatory agency such as the FDA or the EMEA.
  • the formulation may be preserved or non-preserved (not containing Purite®), such as a unit dose version. This version would be the same as that in Table 1 except it would contain no Purite®.
  • the term “effective amount” or “effective dose” means an amount sufficient to achieve the desired result on the process or condition, and it accordingly will depend on the ingredient and the desired result. Nonetheless, once the desired effect is known, determining the effective amount is within the skill of a person skilled in the art.
  • composition and “preparation” as used herein are equivalent terms referring to a composition of matter suitable for pharmaceutical use (i.e., producing a therapeutic effect as well as possessing acceptable pharmacokinetic and toxicological properties).
  • prevent refers to a decrease in the occurrence of dermatological symptoms (e.g., urticardial wheals) in a patient.
  • the prevention may be complete (i.e., no detectable symptoms) or partial, so that fewer symptoms are observed than would likely occur absent treatment.
  • Treatment can refer to any delay in onset, e.g., reduction in the frequency or severity of symptoms, amelioration of symptoms, improvement in patient comfort, reduction in symptoms of dry eye, and the like.
  • the effect of treatment can be compared to an individual or pool of individuals not receiving a given treatment, or to the same patient before, or after cessation of, treatment.
  • terapéuticaally effective amount refers to that amount of the composition or agent in a composition sufficient to ameliorate one or more aspects of the disorder.
  • Therapeutic efficacy can also be expressed as “-fold” increase or decrease.
  • a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
  • Treatment includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of the above. “Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results.
  • Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable.
  • Treating” and “treatment” as used herein may include prophylactic treatment.
  • Treatment methods include administering to a subject a therapeutically effective amount of an active agent.
  • the administering step may consist of a single administration or may include a series of administrations.
  • the length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof.
  • the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required.
  • the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.
  • Delivering lipids to the human tear film to supplement and enhance the native lipid layer, often deficient due to dysfunction of meibomian glands and other causes, is a recognized strategy in treating signs and symptoms of dry eye. This is in theory especially beneficial in low humidity or when other internal/external factors increase tear film evaporation. Excessive loss of water from the tear film causes an increase in salt content and causes hyperosmotic stress to the cells of the ocular surface.
  • the native lipid layer is very thin and the total volume of lipid is a small fraction of the total tear film volume.
  • To enhance the structure and function of the lipid layer by topical application of a lipid-containing drop requires only a small volume of oil to be delivered; excess lipid will displace and disrupt the total aqueous volume, by far the greatest component of tears. It is also necessary that the lipid be delivered quickly, during the brief contact time of a topical eye drop. Finally, the lipid delivered needs to become established as part of the native lipid layer, at the air interface.
  • the challenge of lipid release from an emulsion has been approached by using substantial amounts of lipid (1-5%) and/or building an emulsion system that readily separates.
  • the disadvantage of this approach includes: the product requires shaking, the clarity of the emulsion is greatly reduced, the total volume of lipid delivered to the eye is potentially large and variable and tolerability can be lower than an fully aqueous eye drop.
  • An alternate means of lipid release involves the use of a salt-sensitive emulsion system in a product intended for topical use that is largely free of salt.
  • This system uses a surfactant and viscosity-increasing polymer to hold the lipid (eg. castor oil) in a stable sub-micron emulsion.
  • the natural salt content is sufficient to rapidly cause a drop in product viscosity due to action on the polymer structure. This loss of viscosity allows lipid release to occur to a significantly greater degree and much faster.
  • Efficiency of lipid delivery can be defined as the amount of lipid released from the emulsion, as a proportion of total lipid content, over time under standard test conditions.
  • osmoprotectants (1-carnitine and erythritol) and humectants/lubricants (glycerin and carboxymethylcellulose increases the clinical usefulness of this product to a broader range of dry eye patients than other emulsion systems targeting lipid deficiency or meibomian gland dysfunction.
  • the objective of the study was to evaluate the safety, efficacy, and acceptability of the formulation of Table 1, but without containing Purite®, referred to as a Next Generation Emulsion Unit-dose or (“NGE UD”) in subjects with signs and symptoms of dry eye disease.
  • NGE UD Next Generation Emulsion Unit-dose
  • NGE UD Sensitive Preservative-free Lubricant Eye Drops Unit-dose
  • NGE MD Next Generation Emulsion Multidose
  • OPTIVE MD OPTIVETM Lubricant Eye Drops Multidose
  • the planned study duration was 30 days for each subject and consisted of up to 3 scheduled visits (days 1 [baseline], 7, and 30 [exit]).
  • eligible subjects with signs and symptoms of dry eye disease were assigned according to a 2:2:1:1 treatment allocation ratio to use NGE UD, OPTIVE UD, NGE MD, or OPTIVE MD, respectively.
  • OSDI Ocular Surface Disease Index ⁇
  • Approximately 300 subjects were to be enrolled at 13 to 14 sites within the USA in order to have 288 completed subjects assuming a dropout rate of approximately 5%. Subjects were instructed to instill 1 to 2 drops of their assigned study product in each eye, as needed, but at least 2 times daily for 30 days.
  • the intent-to-treat (ITT) population consisted of all randomized subjects and was used for analyses of efficacy data based on the treatment randomized.
  • the safety population consisted of all treated subjects and was used for analyses of all safety data based on the actual treatment received.
  • the per-protocol (PP) population consisted of randomized subjects who had no major protocol violations, as determined prior to database lock.
  • the primary efficacy variable was the change from baseline in OSDI score at day 30 in the ITT population.
  • the primary efficacy analysis was performed on the change from baseline in OSDI score at day 30 via a 2-way analysis of variance (ANOVA) model with treatment and baseline OSDI stratification as the main effects.
  • ANOVA analysis of variance
  • Noninferiority was tested using a 2-sided confidence interval (CI).
  • the treatment difference and 95% CI in change from baseline in OSDI score at day 30 between NGE UD and OPTIVE UD (NGE UD minus OPTIVE UD) were calculated based on the ANOVA model.
  • Non-inferiority was established if the upper limit of the 95% CI was less than the prespecified margin of 7.3.
  • the Secondary efficacy measures included TBUT, corneal staining, conjunctival staining, and Schirmer test. The raw values of these measures were summarized for the ITT population, with missing data imputation using LOCF at each scheduled follow-up visit. The treatment difference and 95% CI for between-treatment comparisons were calculated. The treatment differences and 95% CIs in change from baseline in OSDI score at day 30 between NGE UD and NGE MD, NGE MD and OPTIVE MD were also analyzed as secondary efficacy variables.
  • the safety variables included adverse events, biomicroscopy, and distance visual acuity. Since both eyes were treated, both eyes were included in the safety analyses.
  • the Medical Dictionary for Regulatory Activities (MedDRA) nomenclature was used to code adverse events.
  • the number and percent of subjects with clinically significant biomicroscopy findings at one or more visits in either eye were tabulated.
  • the overall frequency distribution was analyzed using Pearson's chi-square test. For a clinically significant biomicroscopic finding (more than 1 severity grade increase [worsening] from baseline) with an incidence rate of ⁇ 5% in any treatment group, the mean severity grade and the frequency distribution of severity scores were summarized at each scheduled visit.
  • the mean age of all subjects was 54.8 years (standard deviation 14.33) with 83.2% (262/315) of subjects in the >40 years age group. In addition, 81.0% (255/315) of all subjects were female and 84.4% (266/315) were Caucasian.
  • NGE UD appeared to be well tolerated during the study. The most commonly reported treatment-related adverse events were instillation site pain and vision blurred. Throughout the study, there were no treatment-related serious adverse events. The safety profile was consistent with OPTIVE UD, OPTIVE MD, and NGE MD. This is supportive of the safety of the NGE UD formulation in clinical use, and confirms the safety of the NGE MD formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/708,783 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system Abandoned US20130150324A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/708,783 US20130150324A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US15/078,377 US9907826B2 (en) 2011-12-07 2016-03-23 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US15/878,259 US10888598B2 (en) 2011-12-07 2018-01-23 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US17/128,794 US20210245512A1 (en) 2011-12-07 2020-12-21 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US18/410,273 US20240293491A1 (en) 2011-12-07 2024-01-11 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
US13/708,783 US20130150324A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/708,771 Continuation-In-Part US9314528B2 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US15/078,377 Continuation-In-Part US9907826B2 (en) 2011-12-07 2016-03-23 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (1)

Publication Number Publication Date
US20130150324A1 true US20130150324A1 (en) 2013-06-13

Family

ID=47459152

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/708,783 Abandoned US20130150324A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US13/708,771 Active US9314528B2 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/708,771 Active US9314528B2 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Country Status (27)

Country Link
US (2) US20130150324A1 (enrdf_load_stackoverflow)
EP (5) EP3981387A1 (enrdf_load_stackoverflow)
JP (1) JP6142419B2 (enrdf_load_stackoverflow)
KR (1) KR102017922B1 (enrdf_load_stackoverflow)
CN (2) CN104114152A (enrdf_load_stackoverflow)
AR (1) AR089123A1 (enrdf_load_stackoverflow)
AU (2) AU2012347459A1 (enrdf_load_stackoverflow)
BR (1) BR112014013820A8 (enrdf_load_stackoverflow)
CA (1) CA2858574C (enrdf_load_stackoverflow)
CL (1) CL2014001518A1 (enrdf_load_stackoverflow)
CO (1) CO6990739A2 (enrdf_load_stackoverflow)
DK (2) DK2787968T3 (enrdf_load_stackoverflow)
ES (2) ES2896336T3 (enrdf_load_stackoverflow)
HU (2) HUE057140T2 (enrdf_load_stackoverflow)
IL (1) IL233008A (enrdf_load_stackoverflow)
IN (1) IN2014CN04809A (enrdf_load_stackoverflow)
MX (1) MX355216B (enrdf_load_stackoverflow)
MY (1) MY173378A (enrdf_load_stackoverflow)
PH (2) PH12014501296B1 (enrdf_load_stackoverflow)
PL (2) PL2787969T3 (enrdf_load_stackoverflow)
PT (2) PT2787969T (enrdf_load_stackoverflow)
RU (1) RU2014127074A (enrdf_load_stackoverflow)
SG (1) SG11201403013VA (enrdf_load_stackoverflow)
SI (2) SI2787969T1 (enrdf_load_stackoverflow)
TW (1) TWI652072B (enrdf_load_stackoverflow)
WO (2) WO2013086438A1 (enrdf_load_stackoverflow)
ZA (1) ZA201404228B (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2765987A1 (en) * 2011-10-06 2014-08-20 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
WO2019036625A1 (en) * 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3266446T3 (en) 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
TW202014194A (zh) 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060106104A1 (en) * 2004-11-16 2006-05-18 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US20080207495A1 (en) * 2006-07-25 2008-08-28 Graham Richard S Cyclosporin compositions for ocular rosacea treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) * 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
NZ522610A (en) 2000-07-14 2004-11-26 Allergan Inc Compositions containing therapeutically active components having enhanced solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
WO2002038161A1 (en) 2000-11-08 2002-05-16 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
JP2006504701A (ja) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
WO2004035005A2 (en) * 2002-10-18 2004-04-29 Echols Joel S Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
PT2116227E (pt) * 2003-06-13 2013-06-28 Novartis Ag Composições oftálmicas que contêm uma combinação sinérgica de dois polímeros
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
KR20060121151A (ko) * 2003-11-10 2006-11-28 도레이 가부시끼가이샤 다당류 함유 조성물 및 누액층 안정화 점안제
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
JP2010520210A (ja) * 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
MY172185A (en) * 2009-06-05 2019-11-15 Allergan Inc Artificial tears and therapeutic uses
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060106104A1 (en) * 2004-11-16 2006-05-18 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US20080207495A1 (en) * 2006-07-25 2008-08-28 Graham Richard S Cyclosporin compositions for ocular rosacea treatment

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2765987A1 (en) * 2011-10-06 2014-08-20 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US10888598B2 (en) 2011-12-07 2021-01-12 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
WO2019036625A1 (en) * 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
US11622982B2 (en) 2017-08-18 2023-04-11 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US12220439B2 (en) 2017-08-18 2025-02-11 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye

Also Published As

Publication number Publication date
EP4403220A2 (en) 2024-07-24
BR112014013820A2 (pt) 2017-06-13
ZA201404228B (en) 2015-12-23
EP3981387A1 (en) 2022-04-13
HUE057140T2 (hu) 2022-04-28
EP2787968B1 (en) 2020-03-04
PH12014501296B1 (en) 2023-04-05
SI2787969T1 (sl) 2021-12-31
PL2787969T3 (pl) 2021-12-20
KR102017922B1 (ko) 2019-09-03
PH12021553172A1 (en) 2024-05-27
RU2018119362A3 (enrdf_load_stackoverflow) 2021-09-07
US20130197083A1 (en) 2013-08-01
EP4403220A3 (en) 2024-10-23
EP2787969A1 (en) 2014-10-15
AU2017265181B2 (en) 2019-06-20
CA2858574A1 (en) 2013-06-13
JP2015504860A (ja) 2015-02-16
EP2787969B1 (en) 2021-09-29
CA2858574C (en) 2017-05-30
SI2787968T1 (sl) 2020-08-31
BR112014013820A8 (pt) 2017-06-13
JP6142419B2 (ja) 2017-06-07
CO6990739A2 (es) 2014-07-10
PT2787968T (pt) 2020-06-16
MX2014006804A (es) 2014-09-22
HK1203057A1 (en) 2015-10-16
TW201325633A (zh) 2013-07-01
EP3666257A1 (en) 2020-06-17
ES2896336T3 (es) 2022-02-24
CN108969482A (zh) 2018-12-11
HK1201458A1 (en) 2015-09-04
AU2017265181A1 (en) 2017-12-14
KR20140107383A (ko) 2014-09-04
CN104114152A (zh) 2014-10-22
WO2013086438A1 (en) 2013-06-13
PL2787968T3 (pl) 2020-08-24
MY173378A (en) 2020-01-21
US9314528B2 (en) 2016-04-19
AU2012347459A1 (en) 2014-07-03
DK2787968T3 (da) 2020-06-02
PT2787969T (pt) 2021-11-09
DK2787969T3 (da) 2021-11-01
IL233008A0 (en) 2014-07-31
WO2013086449A1 (en) 2013-06-13
AR089123A1 (es) 2014-07-30
RU2014127074A (ru) 2016-02-10
TWI652072B (zh) 2019-03-01
IL233008A (en) 2017-07-31
CL2014001518A1 (es) 2014-10-24
PH12014501296A1 (en) 2014-10-08
RU2018119362A (ru) 2018-11-08
SG11201403013VA (en) 2014-07-30
HUE049489T2 (hu) 2020-09-28
ES2797650T3 (es) 2020-12-03
IN2014CN04809A (enrdf_load_stackoverflow) 2015-09-18
MX355216B (es) 2018-04-10
EP2787968A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
AU2017265181B2 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20240108677A1 (en) Artificial tears and therapeutic uses
US20240293491A1 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2827426T3 (es) Composición oftálmica para la protección corneal
JPWO2018074421A1 (ja) 眼科用剤及び眼科用薬
EP3968949A1 (en) Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
HK1203057B (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ743307A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ743307B2 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
WO2025175150A1 (en) Enhanced artificial tear formulations
US20190224136A1 (en) Artificial tear compositions and methods of use thereof
HK1169046A (en) Artificial tears and therapeutic uses

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEHIGE, JOSEPH G.;SIMMONS, PETER A.;REEL/FRAME:029670/0259

Effective date: 20130121

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION